Skip to content

Author

Bhagirathbhai R. Dholaria

We have 3 of 317 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.

A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al. · 0 citations
Open access Aug 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.

Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al. · 0 citations
Sep 2026

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Pirtobrutinib and CAR T-cell therapy and CAR T-cell therapy have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors.

A. Zelenetz, Leo I. Gordon, Jeremy S. Abramson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.